The FDA urges healthcare professionals to stop administering the products, and patients should stop using them.

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

It also said it would not take enforcement action — for now — against pharmacies making their own versions of weight-loss drugs based ... transitioning to the FDA-approved drug,” Scott ...

FDA approval: Ozempic is FDA-approved for Type 2 diabetes, while Wegovy is FDA-approved for weight loss. Cost: Ozempic is ...

Wegovy® is the only version of semaglutide that is FDA-approved for weight loss, while Ozempic® and other forms of the drug ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

Compounded semaglutide can be an affordable alternative to brand-name weight loss injections like Ozempic and Wegovy. But ...

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a shortage of the brand-name drug has ended – which means compounding of the ...

But she also emphasized that GLP-1 medications like Mounjaro are Ozempic are not the only options when it comes to weight loss or diabetes, and signficantly more affordable FDA-approved options do ...

Novo Nordisk said on Wednesday it was aware of reports of 10 deaths and 100 hospitalizations of people who had taken ...

The controlling shareholder in Novo Nordisk put in a request for EU approval for the deal on Oct. 31. The EU antitrust ...